Mechanism of Action
AOD-9604 derives its metabolic effects from a distinct receptor pathway compared to full-length GH.
Beta-3 Adrenergic Receptor Activation
AOD-9604 activates beta-3 adrenergic receptors (ADRB3) expressed primarily in adipose tissue and the GI tract. ADRB3 activation in adipocytes stimulates lipolysis via cAMP-mediated activation of hormone-sensitive lipase (HSL), releasing stored triglycerides as free fatty acids for oxidation. This is the primary fat-burning mechanism.[1]Lipogenesis Inhibition
AOD-9604 also inhibits fatty acid synthase (FAS) and acetyl-CoA carboxylase in adipocytes, reducing the rate of de novo lipogenesis (new fat synthesis). This dual mechanism, increased fat breakdown + reduced new fat synthesis - contributes to net fat loss.[2]No IGF-1 or Insulin Effect
A critical distinction from full-length GH: AOD-9604 does not bind the GH receptor, does not elevate IGF-1, and does not cause insulin resistance. This makes it metabolically cleaner than GH for pure fat loss applications without the anabolic, diabetogenic, or tissue-growth effects of exogenous GH.[1]Research Overview
Fat Loss and Body Composition
Phase IIb ClinicalPhase IIb trials in obese adults demonstrated statistically significant fat mass reduction versus placebo at 1 mg/day oral dose over 12 weeks. Subcutaneous route shows superior pharmacokinetics. Animal studies show 50% reduction in fat accumulation on high-fat diet with AOD-9604.[1]
Osteoarthritis Cartilage Repair
Phase II ClinicalAOD-9604 has shown chondrocyte stimulation properties, increasing cartilage matrix synthesis and reducing degradative enzymes in articular cartilage. Phase IIb trials in knee osteoarthritis (intra-articular injection) showed promising symptom and structural endpoints.[3]
GRAS Status
RegulatoryAOD-9604 received FDA GRAS designation as a food ingredient, providing a regulatory basis supporting its safety profile. GRAS designation requires substantial safety data, this distinguishes AOD-9604 from most peptides lacking formal regulatory recognition.[2]
Calculate your AOD-9604 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Fat loss | 250–500 µg | Once daily (fasted morning) | Subcutaneous |
| GH axis stack (fat focused) | 300 µg AOD + 200 µg Ipamorelin | Morning fasted | Subcutaneous |
| Cartilage support | 500 µg | Once daily | Subcutaneous |
Fasted morning dosing is strongly recommended, insulin suppresses lipolysis and would blunt AOD-9604 fat-releasing effects. Administration 30-60 min before exercise further amplifies fat oxidation by ensuring elevated free fatty acids are available for burning.
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
AOD-9604 has one of the strongest safety profiles among research peptides due to its clinical trial history and GRAS designation.
WADA: Prohibited as a GH fragment / peptide hormone. Athletes subject to testing must not use this compound.
FDA GRAS: Generally Recognized as Safe designation as a food ingredient, a formal safety recognition uncommon for peptide compounds.
No IGF-1 elevation: Avoids cancer risk concerns associated with supraphysiological IGF-1 from exogenous GH.
No insulin resistance: Does not cause the glucose dysregulation associated with GH administration.
Phase IIb safety data: Clinically evaluated without dose-limiting toxicities. Mild injection site reactions are the most common adverse effect.
References
- [1]Heffernan MA, et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knockout mice." Endocrinology. 2001;142(12):5182-5189.
- [2]Ng FM, et al. "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Horm Res. 2000;53(6):274-278.
- [3]Wellard RM, et al. "AOD9604 cartilage regeneration study." Cartilage. 2011;2(1):28-36.